CA2446582A1 - Reagents and methods for modulating dkk-mediated interactions - Google Patents
Reagents and methods for modulating dkk-mediated interactions Download PDFInfo
- Publication number
- CA2446582A1 CA2446582A1 CA002446582A CA2446582A CA2446582A1 CA 2446582 A1 CA2446582 A1 CA 2446582A1 CA 002446582 A CA002446582 A CA 002446582A CA 2446582 A CA2446582 A CA 2446582A CA 2446582 A1 CA2446582 A1 CA 2446582A1
- Authority
- CA
- Canada
- Prior art keywords
- dkk
- hbm
- lrp5
- protein
- lrp6
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 252
- 230000003993 interaction Effects 0.000 title claims abstract description 96
- 230000001404 mediated effect Effects 0.000 title claims description 32
- 239000003153 chemical reaction reagent Substances 0.000 title abstract description 24
- 101001043594 Homo sapiens Low-density lipoprotein receptor-related protein 5 Proteins 0.000 claims abstract description 322
- 102100021926 Low-density lipoprotein receptor-related protein 5 Human genes 0.000 claims abstract description 321
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 claims abstract description 288
- 101710099518 Dickkopf-related protein 1 Proteins 0.000 claims abstract description 287
- 101000990228 Homo sapiens Hemoglobin subunit mu Proteins 0.000 claims abstract description 197
- 150000001875 compounds Chemical class 0.000 claims abstract description 192
- 101001039199 Homo sapiens Low-density lipoprotein receptor-related protein 6 Proteins 0.000 claims abstract description 179
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 179
- 102100040704 Low-density lipoprotein receptor-related protein 6 Human genes 0.000 claims abstract description 178
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 171
- 102000013814 Wnt Human genes 0.000 claims abstract description 125
- 108050003627 Wnt Proteins 0.000 claims abstract description 125
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 116
- 239000000203 mixture Substances 0.000 claims abstract description 114
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 106
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 106
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 84
- 150000002632 lipids Chemical class 0.000 claims abstract description 59
- 230000011664 signaling Effects 0.000 claims abstract description 41
- 238000003556 assay Methods 0.000 claims abstract description 27
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 458
- 102000004169 proteins and genes Human genes 0.000 claims description 345
- 230000027455 binding Effects 0.000 claims description 179
- 210000004027 cell Anatomy 0.000 claims description 175
- 239000012634 fragment Substances 0.000 claims description 145
- 230000000694 effects Effects 0.000 claims description 132
- 230000014509 gene expression Effects 0.000 claims description 98
- 108010079855 Peptide Aptamers Proteins 0.000 claims description 90
- 241001465754 Metazoa Species 0.000 claims description 48
- 230000037361 pathway Effects 0.000 claims description 44
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 claims description 40
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 39
- 239000002773 nucleotide Substances 0.000 claims description 38
- 125000003729 nucleotide group Chemical group 0.000 claims description 38
- 108020004999 messenger RNA Proteins 0.000 claims description 35
- 230000009261 transgenic effect Effects 0.000 claims description 32
- 241000282414 Homo sapiens Species 0.000 claims description 30
- 241000269370 Xenopus <genus> Species 0.000 claims description 28
- 210000001519 tissue Anatomy 0.000 claims description 28
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 27
- 108020001507 fusion proteins Proteins 0.000 claims description 26
- 102000037865 fusion proteins Human genes 0.000 claims description 26
- 239000003550 marker Substances 0.000 claims description 25
- 239000013598 vector Substances 0.000 claims description 25
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 23
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 23
- 230000000692 anti-sense effect Effects 0.000 claims description 22
- -1 Gcn4 Proteins 0.000 claims description 21
- 108020004459 Small interfering RNA Proteins 0.000 claims description 19
- 239000004055 small Interfering RNA Substances 0.000 claims description 19
- 239000007787 solid Substances 0.000 claims description 19
- 208000010392 Bone Fractures Diseases 0.000 claims description 18
- 230000037182 bone density Effects 0.000 claims description 18
- 238000012216 screening Methods 0.000 claims description 18
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 17
- 238000012360 testing method Methods 0.000 claims description 17
- 230000004568 DNA-binding Effects 0.000 claims description 16
- 101000992274 Homo sapiens Olfactory receptor 5L1 Proteins 0.000 claims description 16
- 102100031825 Olfactory receptor 5L1 Human genes 0.000 claims description 16
- 208000035475 disorder Diseases 0.000 claims description 16
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 16
- 239000011707 mineral Substances 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 15
- 230000035772 mutation Effects 0.000 claims description 15
- 210000005253 yeast cell Anatomy 0.000 claims description 15
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims description 14
- 108700008625 Reporter Genes Proteins 0.000 claims description 14
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 14
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 14
- 230000001105 regulatory effect Effects 0.000 claims description 14
- 230000004156 Wnt signaling pathway Effects 0.000 claims description 13
- 230000003247 decreasing effect Effects 0.000 claims description 13
- 230000001965 increasing effect Effects 0.000 claims description 13
- 230000004913 activation Effects 0.000 claims description 12
- 230000007423 decrease Effects 0.000 claims description 12
- 108700020987 Wnt-1 Proteins 0.000 claims description 11
- 102000052547 Wnt-1 Human genes 0.000 claims description 11
- 230000001054 cortical effect Effects 0.000 claims description 11
- 102000040430 polynucleotide Human genes 0.000 claims description 11
- 108091033319 polynucleotide Proteins 0.000 claims description 11
- 239000002157 polynucleotide Substances 0.000 claims description 11
- 239000000758 substrate Substances 0.000 claims description 11
- 239000003446 ligand Substances 0.000 claims description 10
- 239000013612 plasmid Substances 0.000 claims description 10
- 201000001320 Atherosclerosis Diseases 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 9
- 241000288906 Primates Species 0.000 claims description 9
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 9
- 230000037118 bone strength Effects 0.000 claims description 9
- 102000005962 receptors Human genes 0.000 claims description 9
- 108020003175 receptors Proteins 0.000 claims description 9
- 239000005089 Luciferase Substances 0.000 claims description 8
- 241000235070 Saccharomyces Species 0.000 claims description 8
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 7
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 7
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 7
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 239000005090 green fluorescent protein Substances 0.000 claims description 7
- 108010083590 Apoproteins Proteins 0.000 claims description 6
- 102000006410 Apoproteins Human genes 0.000 claims description 6
- 108010001515 Galectin 4 Proteins 0.000 claims description 6
- 102100039556 Galectin-4 Human genes 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 6
- 210000001109 blastomere Anatomy 0.000 claims description 6
- 238000012217 deletion Methods 0.000 claims description 6
- 230000037430 deletion Effects 0.000 claims description 6
- 241000283690 Bos taurus Species 0.000 claims description 5
- 241000283073 Equus caballus Species 0.000 claims description 5
- 108060001084 Luciferase Proteins 0.000 claims description 5
- 102000052549 Wnt-3 Human genes 0.000 claims description 5
- 108700020985 Wnt-3 Proteins 0.000 claims description 5
- 239000005557 antagonist Substances 0.000 claims description 5
- 230000008416 bone turnover Effects 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- 238000002866 fluorescence resonance energy transfer Methods 0.000 claims description 5
- 208000005368 osteomalacia Diseases 0.000 claims description 5
- 101150111329 ACE-1 gene Proteins 0.000 claims description 4
- 241000271566 Aves Species 0.000 claims description 4
- 101100490563 Caenorhabditis elegans adr-1 gene Proteins 0.000 claims description 4
- 241000282465 Canis Species 0.000 claims description 4
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 claims description 4
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 claims description 4
- 241000282324 Felis Species 0.000 claims description 4
- 101150009243 HAP1 gene Proteins 0.000 claims description 4
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 claims description 4
- 208000037147 Hypercalcaemia Diseases 0.000 claims description 4
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 claims description 4
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims description 4
- 208000010191 Osteitis Deformans Diseases 0.000 claims description 4
- 208000027868 Paget disease Diseases 0.000 claims description 4
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 claims description 4
- 241000283984 Rodentia Species 0.000 claims description 4
- 101710204410 Scaffold protein Proteins 0.000 claims description 4
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims description 4
- 201000001386 familial hypercholesterolemia Diseases 0.000 claims description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
- 230000000148 hypercalcaemia Effects 0.000 claims description 4
- 208000030915 hypercalcemia disease Diseases 0.000 claims description 4
- 208000027202 mammary Paget disease Diseases 0.000 claims description 4
- 108020004017 nuclear receptors Proteins 0.000 claims description 4
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims description 4
- 101150020580 yap1 gene Proteins 0.000 claims description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 3
- 206010005954 Bone development abnormal Diseases 0.000 claims description 3
- 208000020084 Bone disease Diseases 0.000 claims description 3
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 3
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 3
- 201000001376 Familial Combined Hyperlipidemia Diseases 0.000 claims description 3
- 206010059183 Familial hypertriglyceridaemia Diseases 0.000 claims description 3
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 claims description 3
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 claims description 3
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 claims description 3
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 claims description 3
- 208000001021 Hyperlipoproteinemia Type I Diseases 0.000 claims description 3
- 201000010252 Hyperlipoproteinemia Type III Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 206010031243 Osteogenesis imperfecta Diseases 0.000 claims description 3
- 206010031252 Osteomyelitis Diseases 0.000 claims description 3
- 101001124893 Xenopus laevis Nodal homolog 3-A Proteins 0.000 claims description 3
- 230000000747 cardiac effect Effects 0.000 claims description 3
- 230000007812 deficiency Effects 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 201000010934 exostosis Diseases 0.000 claims description 3
- 201000011110 familial lipoprotein lipase deficiency Diseases 0.000 claims description 3
- 208000020887 hyperlipoproteinemia type 3 Diseases 0.000 claims description 3
- 208000000522 hyperlipoproteinemia type IV Diseases 0.000 claims description 3
- 201000010930 hyperostosis Diseases 0.000 claims description 3
- 230000003100 immobilizing effect Effects 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 208000007442 rickets Diseases 0.000 claims description 3
- 101150103084 siamois gene Proteins 0.000 claims description 3
- 101150118060 trxA gene Proteins 0.000 claims description 3
- 102000052510 DNA-Binding Proteins Human genes 0.000 claims description 2
- 101710096438 DNA-binding protein Proteins 0.000 claims description 2
- 101150047834 SNAI2 gene Proteins 0.000 claims description 2
- 102000007451 Steroid Receptors Human genes 0.000 claims description 2
- 108010085012 Steroid Receptors Proteins 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 210000005257 cortical tissue Anatomy 0.000 claims description 2
- 238000010998 test method Methods 0.000 claims description 2
- 238000000225 bioluminescence resonance energy transfer Methods 0.000 claims 2
- 102000007399 Nuclear hormone receptor Human genes 0.000 claims 1
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 claims 1
- 101150005828 SWI5 gene Proteins 0.000 claims 1
- 101150066555 lacZ gene Proteins 0.000 claims 1
- 210000005228 liver tissue Anatomy 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 abstract description 59
- 238000011282 treatment Methods 0.000 abstract description 23
- 230000002159 abnormal effect Effects 0.000 abstract description 5
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 230000005754 cellular signaling Effects 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 302
- 108091023037 Aptamer Proteins 0.000 description 54
- 108020004414 DNA Proteins 0.000 description 42
- 239000003795 chemical substances by application Substances 0.000 description 42
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 34
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 30
- 230000000295 complement effect Effects 0.000 description 24
- 238000001086 yeast two-hybrid system Methods 0.000 description 24
- 201000010099 disease Diseases 0.000 description 23
- 108020004511 Recombinant DNA Proteins 0.000 description 22
- 239000000523 sample Substances 0.000 description 22
- 239000002299 complementary DNA Substances 0.000 description 21
- 108020001756 ligand binding domains Proteins 0.000 description 20
- 235000001014 amino acid Nutrition 0.000 description 19
- 206010017076 Fracture Diseases 0.000 description 16
- 235000012000 cholesterol Nutrition 0.000 description 16
- 230000006870 function Effects 0.000 description 16
- 108091034117 Oligonucleotide Proteins 0.000 description 15
- 238000009396 hybridization Methods 0.000 description 15
- 150000001413 amino acids Chemical class 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 14
- 238000003752 polymerase chain reaction Methods 0.000 description 14
- 238000000338 in vitro Methods 0.000 description 13
- 238000013518 transcription Methods 0.000 description 13
- 230000035897 transcription Effects 0.000 description 13
- 210000001161 mammalian embryo Anatomy 0.000 description 12
- 108091026890 Coding region Proteins 0.000 description 11
- 108010007622 LDL Lipoproteins Proteins 0.000 description 11
- 102000007330 LDL Lipoproteins Human genes 0.000 description 11
- 230000001413 cellular effect Effects 0.000 description 11
- 238000011161 development Methods 0.000 description 11
- 239000000284 extract Substances 0.000 description 11
- 230000002068 genetic effect Effects 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 11
- 239000013615 primer Substances 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 108010010234 HDL Lipoproteins Proteins 0.000 description 10
- 102000015779 HDL Lipoproteins Human genes 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 10
- 210000002257 embryonic structure Anatomy 0.000 description 10
- 230000007246 mechanism Effects 0.000 description 10
- 101710099523 Dickkopf-related protein 2 Proteins 0.000 description 9
- 102100030091 Dickkopf-related protein 2 Human genes 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 108010001831 LDL receptors Proteins 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 8
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 8
- 102000004895 Lipoproteins Human genes 0.000 description 8
- 108090001030 Lipoproteins Proteins 0.000 description 8
- 230000004075 alteration Effects 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 8
- 230000004071 biological effect Effects 0.000 description 8
- 230000019491 signal transduction Effects 0.000 description 8
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 7
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 7
- 208000006386 Bone Resorption Diseases 0.000 description 7
- 102000053602 DNA Human genes 0.000 description 7
- 101000864646 Homo sapiens Dickkopf-related protein 1 Proteins 0.000 description 7
- 230000014461 bone development Effects 0.000 description 7
- 229940112869 bone morphogenetic protein Drugs 0.000 description 7
- 230000024279 bone resorption Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 210000000963 osteoblast Anatomy 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 241000894007 species Species 0.000 description 7
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- 238000008214 LDL Cholesterol Methods 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 108010016283 TCF Transcription Factors Proteins 0.000 description 6
- 102000000479 TCF Transcription Factors Human genes 0.000 description 6
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 235000018417 cysteine Nutrition 0.000 description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 102000014914 Carrier Proteins Human genes 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 239000012736 aqueous medium Substances 0.000 description 5
- 210000002449 bone cell Anatomy 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 229940011871 estrogen Drugs 0.000 description 5
- 239000000262 estrogen Substances 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 230000011164 ossification Effects 0.000 description 5
- 230000004952 protein activity Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 230000032258 transport Effects 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 102000055006 Calcitonin Human genes 0.000 description 4
- 108060001064 Calcitonin Proteins 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 102100037985 Dickkopf-related protein 3 Human genes 0.000 description 4
- 101710099550 Dickkopf-related protein 3 Proteins 0.000 description 4
- 102100037986 Dickkopf-related protein 4 Human genes 0.000 description 4
- 101710099554 Dickkopf-related protein 4 Proteins 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 101150103172 HBM gene Proteins 0.000 description 4
- 108010046315 IDL Lipoproteins Proteins 0.000 description 4
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 4
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 102000002933 Thioredoxin Human genes 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 108091008324 binding proteins Proteins 0.000 description 4
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 4
- 229960004015 calcitonin Drugs 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 150000001840 cholesterol esters Chemical class 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 230000037356 lipid metabolism Effects 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 230000001582 osteoblastic effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000007634 remodeling Methods 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 102000014452 scavenger receptors Human genes 0.000 description 4
- 108060008226 thioredoxin Proteins 0.000 description 4
- 229940094937 thioredoxin Drugs 0.000 description 4
- 238000012085 transcriptional profiling Methods 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 3
- 102100026189 Beta-galactosidase Human genes 0.000 description 3
- 229940122361 Bisphosphonate Drugs 0.000 description 3
- 206010065687 Bone loss Diseases 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102000012422 Collagen Type I Human genes 0.000 description 3
- 108010022452 Collagen Type I Proteins 0.000 description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 241000252212 Danio rerio Species 0.000 description 3
- 102100037981 Dickkopf-like protein 1 Human genes 0.000 description 3
- 102100031780 Endonuclease Human genes 0.000 description 3
- 241000206602 Eukaryota Species 0.000 description 3
- 206010020100 Hip fracture Diseases 0.000 description 3
- 101000951345 Homo sapiens Dickkopf-like protein 1 Proteins 0.000 description 3
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 3
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 3
- 108091092195 Intron Proteins 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102000014736 Notch Human genes 0.000 description 3
- 108010070047 Notch Receptors Proteins 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 206010039984 Senile osteoporosis Diseases 0.000 description 3
- 102100039066 Very low-density lipoprotein receptor Human genes 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- 150000004663 bisphosphonates Chemical class 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000010072 bone remodeling Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 108091092328 cellular RNA Proteins 0.000 description 3
- 108010008846 chordin Proteins 0.000 description 3
- 102000006533 chordin Human genes 0.000 description 3
- 239000003636 conditioned culture medium Substances 0.000 description 3
- 210000001671 embryonic stem cell Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000003197 gene knockdown Methods 0.000 description 3
- 230000030279 gene silencing Effects 0.000 description 3
- 230000009368 gene silencing by RNA Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 238000013537 high throughput screening Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 3
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000003716 mesoderm Anatomy 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 238000000520 microinjection Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 102000006255 nuclear receptors Human genes 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 201000008968 osteosarcoma Diseases 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000003571 reporter gene assay Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000012340 reverse transcriptase PCR Methods 0.000 description 3
- 108010078070 scavenger receptors Proteins 0.000 description 3
- 230000037432 silent mutation Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 238000010396 two-hybrid screening Methods 0.000 description 3
- 102000009310 vitamin D receptors Human genes 0.000 description 3
- 108050000156 vitamin D receptors Proteins 0.000 description 3
- 235000012431 wafers Nutrition 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 206010008723 Chondrodystrophy Diseases 0.000 description 2
- 108010004103 Chylomicrons Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 208000025962 Crush injury Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 208000003263 MASS syndrome Diseases 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 108010023795 VLDL receptor Proteins 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 238000002820 assay format Methods 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000033558 biomineral tissue development Effects 0.000 description 2
- 230000008777 canonical pathway Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 238000000749 co-immunoprecipitation Methods 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000001739 density measurement Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000002222 downregulating effect Effects 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000009164 estrogen replacement therapy Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000012226 gene silencing method Methods 0.000 description 2
- 230000009395 genetic defect Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 210000002980 germ line cell Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000003468 luciferase reporter gene assay Methods 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 210000004914 menses Anatomy 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 238000000734 protein sequencing Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000007781 signaling event Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 1
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical class O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- KEWSCDNULKOKTG-UHFFFAOYSA-N 4-cyano-4-ethylsulfanylcarbothioylsulfanylpentanoic acid Chemical compound CCSC(=S)SC(C)(C#N)CCC(O)=O KEWSCDNULKOKTG-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 101100288502 Arabidopsis thaliana LBD1 gene Proteins 0.000 description 1
- 101100234947 Arabidopsis thaliana LBD4 gene Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000713842 Avian sarcoma virus Species 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 102000053028 CD36 Antigens Human genes 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700114 Chinchillidae Species 0.000 description 1
- 102100037637 Cholesteryl ester transfer protein Human genes 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 235000016795 Cola Nutrition 0.000 description 1
- 244000228088 Cola acuminata Species 0.000 description 1
- 235000011824 Cola pachycarpa Nutrition 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000009692 Colles' Fracture Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000004435 EPR spectroscopy Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 102100028466 Frizzled-8 Human genes 0.000 description 1
- 101710140933 Frizzled-8 Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- JMBQKKAJIKAWKF-UHFFFAOYSA-N Glutethimide Chemical compound C=1C=CC=CC=1C1(CC)CCC(=O)NC1=O JMBQKKAJIKAWKF-UHFFFAOYSA-N 0.000 description 1
- 108010001483 Glycogen Synthase Proteins 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102100040615 Homeobox protein MSX-2 Human genes 0.000 description 1
- 101000880514 Homo sapiens Cholesteryl ester transfer protein Proteins 0.000 description 1
- 101100394362 Homo sapiens HBM gene Proteins 0.000 description 1
- 101000967222 Homo sapiens Homeobox protein MSX-2 Proteins 0.000 description 1
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 description 1
- 101000972291 Homo sapiens Lymphoid enhancer-binding factor 1 Proteins 0.000 description 1
- 101001130226 Homo sapiens Phosphatidylcholine-sterol acyltransferase Proteins 0.000 description 1
- 101000666934 Homo sapiens Very low-density lipoprotein receptor Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
- 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 102000011965 Lipoprotein Receptors Human genes 0.000 description 1
- 108010061306 Lipoprotein Receptors Proteins 0.000 description 1
- 102000001851 Low Density Lipoprotein Receptor-Related Protein-1 Human genes 0.000 description 1
- 108010015340 Low Density Lipoprotein Receptor-Related Protein-1 Proteins 0.000 description 1
- 102100022699 Lymphoid enhancer-binding factor 1 Human genes 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102100025246 Neurogenic locus notch homolog protein 2 Human genes 0.000 description 1
- 108700037064 Neurogenic locus notch homolog protein 2 Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 101800001628 Notch 1 intracellular domain Proteins 0.000 description 1
- 102400000552 Notch 1 intracellular domain Human genes 0.000 description 1
- 230000005913 Notch signaling pathway Effects 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 208000004286 Osteochondrodysplasias Diseases 0.000 description 1
- 208000001164 Osteoporotic Fractures Diseases 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 208000016012 Phenotypic abnormality Diseases 0.000 description 1
- 102100031538 Phosphatidylcholine-sterol acyltransferase Human genes 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 102000012412 Presenilin-1 Human genes 0.000 description 1
- 108010036933 Presenilin-1 Proteins 0.000 description 1
- 102000015499 Presenilins Human genes 0.000 description 1
- 108010050254 Presenilins Proteins 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010066717 Q beta Replicase Proteins 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 101150086605 Runx2 gene Proteins 0.000 description 1
- 108091005487 SCARB1 Proteins 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005250 Spontaneous Fractures Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102100037116 Transcription elongation factor 1 homolog Human genes 0.000 description 1
- 108050005285 Transcription factor 7-like 1 Proteins 0.000 description 1
- 102100038313 Transcription factor E2-alpha Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 101150019524 WNT2 gene Proteins 0.000 description 1
- 108700020986 Wnt-2 Proteins 0.000 description 1
- 102000052556 Wnt-2 Human genes 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940062527 alendronate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000002788 anti-peptide Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 208000021018 autosomal dominant inheritance Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000002617 bone density conservation agent Substances 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000037186 bone physiology Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 238000001386 capillary affinity electrophoresis Methods 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000005189 cardiac health Effects 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 208000014884 cartilage development disease Diseases 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000035567 cellular accumulation Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000031154 cholesterol homeostasis Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 108020002632 colipase Proteins 0.000 description 1
- 102000005311 colipase Human genes 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000033035 connective tissue development Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000005014 ectopic expression Effects 0.000 description 1
- 230000004821 effect on bone Effects 0.000 description 1
- 210000003890 endocrine cell Anatomy 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000009123 feedback regulation Effects 0.000 description 1
- 210000002436 femur neck Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229960002972 glutethimide Drugs 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 108010064060 high density lipoprotein receptors Proteins 0.000 description 1
- 102000054823 high-density lipoprotein particle receptor activity proteins Human genes 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 210000000982 limb bud Anatomy 0.000 description 1
- 230000004576 lipid-binding Effects 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 108091005485 macrophage scavenger receptors Proteins 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 238000012775 microarray technology Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000000933 neural crest Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000001020 neural plate Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000008779 noncanonical pathway Effects 0.000 description 1
- 108091008104 nucleic acid aptamers Proteins 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000006548 oncogenic transformation Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000001599 osteoclastic effect Effects 0.000 description 1
- 230000003256 osteocytic effect Effects 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000003234 polygenic effect Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000005373 porous glass Substances 0.000 description 1
- 230000000270 postfertilization Effects 0.000 description 1
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 101150031139 pth gene Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000002165 resonance energy transfer Methods 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 102200087501 rs104894110 Human genes 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 210000002023 somite Anatomy 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000003335 steric effect Effects 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 230000000365 steroidogenetic effect Effects 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 238000011820 transgenic animal model Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000000225 tumor suppressor protein Substances 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000003160 two-hybrid assay Methods 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/50—Amphibians, e.g. Xenopus
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0393—Animal model comprising a reporter system for screening tests
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29131101P | 2001-05-17 | 2001-05-17 | |
| US60/291,311 | 2001-05-17 | ||
| US35305802P | 2002-02-01 | 2002-02-01 | |
| US60/353,058 | 2002-02-01 | ||
| US36129302P | 2002-03-04 | 2002-03-04 | |
| US60/361,293 | 2002-03-04 | ||
| PCT/US2002/015982 WO2002092015A2 (en) | 2001-05-17 | 2002-05-17 | Reagents and methods for modulating dkk-mediated interactions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2446582A1 true CA2446582A1 (en) | 2002-11-21 |
Family
ID=27404041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002446582A Abandoned CA2446582A1 (en) | 2001-05-17 | 2002-05-17 | Reagents and methods for modulating dkk-mediated interactions |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1395285A4 (ja) |
| JP (2) | JP2005512508A (ja) |
| AU (1) | AU2002342734B2 (ja) |
| BR (1) | BR0209836A (ja) |
| CA (1) | CA2446582A1 (ja) |
| IL (1) | IL158750A0 (ja) |
| WO (1) | WO2002092015A2 (ja) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107760686A (zh) * | 2016-08-23 | 2018-03-06 | 上海伯豪医学检验所有限公司 | Dkk‑1蛋白的核酸适配体及其应用 |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2342152T3 (es) | 2002-04-17 | 2010-07-02 | Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Metodo para identificacion de un compuesto para modulacion de la cascada de señales wnt. |
| US7642238B2 (en) * | 2002-12-05 | 2010-01-05 | Shaughnessy John D | Molecular determinants of myeloma bone disease and uses thereof |
| WO2004053063A2 (en) * | 2002-12-05 | 2004-06-24 | The Board Of Trustees Of The University Of Arkansas System | Molecular determinants of myeloma bone disease and uses thereof |
| US8124087B2 (en) | 2002-12-05 | 2012-02-28 | Board Of Trustees Of The University Of Arkansas | Methods of controlling bone loss by inhibiting DKK1 |
| WO2005009346A2 (en) * | 2003-06-24 | 2005-02-03 | Mirus Corporation | Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo |
| US8637506B2 (en) * | 2003-09-22 | 2014-01-28 | Enzo Biochem, Inc. | Compositions and methods for bone formation and remodeling |
| US9046537B2 (en) | 2003-09-22 | 2015-06-02 | Enzo Biochem, Inc. | Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain |
| US8367822B2 (en) | 2003-09-22 | 2013-02-05 | Enzo Therapeutics, Inc. | Compositions and methods for bone formation and remodeling |
| US7473770B2 (en) | 2003-11-17 | 2009-01-06 | Merck & Co., Inc. | Cynomolgus monkey dickkopf-4, nucleotides encoding same, and uses thereof |
| WO2005049640A2 (en) | 2003-11-17 | 2005-06-02 | Merck & Co., Inc. | Rhesus monkey dickkopf-1, nucleotides encoding same, and uses thereof |
| US9052324B2 (en) | 2004-05-19 | 2015-06-09 | Enzo Biochem, Inc. | Compounds and assays for controlling Wnt activity |
| EP2336177A1 (en) | 2004-08-04 | 2011-06-22 | Amgen, Inc | Antibodies to DKK-1 |
| WO2006015497A1 (en) * | 2004-08-13 | 2006-02-16 | Val-Chum, S.E.C. | Methods of use of a dkk1 protein, immunogenic polypeptides thereof, nucleic acid encoding the dkk1 protein or polypeptides, or ligands thereof for detecting tumors; and for eliciting immune response against tumors |
| WO2008097510A1 (en) * | 2007-02-08 | 2008-08-14 | Merck & Co., Inc. | Antibodies specific for dkk-1 |
| WO2009056634A2 (en) * | 2007-11-02 | 2009-05-07 | Novartis Ag | Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (lrp6) |
| AR075989A1 (es) | 2009-04-10 | 2011-05-11 | Lilly Co Eli | Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria |
| AU2010245833B2 (en) * | 2009-05-07 | 2014-03-27 | Novartis Ag | Compositions and methods of use for binding molecules to Dickkopf-1 or Dickkopf-4 or both |
| JP2012526542A (ja) * | 2009-05-12 | 2012-11-01 | ファイザー・インク | 遮断抗ｄｋｋ−１抗体およびその使用 |
| CA2790200A1 (en) * | 2010-02-19 | 2011-08-25 | The Board Of Regents Of The University Of Oklahoma | Monoclonal antibodies that inhibit the wnt signaling pathway and methods of production and use thereof |
| WO2011119661A1 (en) | 2010-03-24 | 2011-09-29 | Genentech, Inc. | Anti-lrp6 antibodies |
| CN103237811A (zh) | 2010-05-06 | 2013-08-07 | 诺瓦提斯公司 | 用于治疗性低密度脂蛋白相关蛋白质6(lrp6)多价抗体的组合物及使用方法 |
| CN103038258B (zh) | 2010-05-06 | 2017-02-15 | 诺华股份有限公司 | 用于治疗低密度脂蛋白相关蛋白质6(lrp6)的抗体的组合物及使用方法 |
| AR088633A1 (es) | 2011-11-04 | 2014-06-25 | Novartis Ag | Constructos extensores de vida media de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) |
| EP3600418A4 (en) * | 2017-03-24 | 2021-01-13 | Yale University | LOW DENSITY LIPOPROTEIN RECEPTOR-BOUND PROTEIN-5 INHIBITION WHICH SUPPRESSES TUMOR FORMATION |
| MY200744A (en) | 2017-05-31 | 2024-01-13 | Boehringer Ingelheim Int | Polypeptides antagonizing wnt signaling in tumor cells |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0988379B1 (en) * | 1997-04-15 | 2007-04-11 | The Wellcome Trust Limited as Trustee to the Wellcome Trust | Ldl-receptor |
| EP1161445A2 (en) * | 1999-03-05 | 2001-12-12 | Millennium Pharmaceuticals, Inc. | Human dickkopf-related protein and nucleic acid molecules and uses therefor |
| IL151904A0 (en) * | 2000-04-05 | 2003-04-10 | Genome Therapeutics Corp | THE HIGH BONE MASS GENE OF 11q13.3 |
| DE60129433T2 (de) * | 2000-05-26 | 2008-04-17 | Oscient Pharmaceuticals Corp., Waltham | Regulation des lipidniveaus über die gene zmax1 oder hbm |
| IL157328A0 (en) * | 2001-02-16 | 2004-02-19 | Genentech Inc | Treatment involving dkk-1 or antagonists thereof |
| JP2004537289A (ja) * | 2001-05-11 | 2004-12-16 | ゲノム セラピューティックス コーポレーション | 骨量および脂質レベルを調整するｈｂｍ変異型 |
-
2002
- 2002-05-17 AU AU2002342734A patent/AU2002342734B2/en not_active Ceased
- 2002-05-17 WO PCT/US2002/015982 patent/WO2002092015A2/en active IP Right Grant
- 2002-05-17 CA CA002446582A patent/CA2446582A1/en not_active Abandoned
- 2002-05-17 JP JP2002588934A patent/JP2005512508A/ja not_active Withdrawn
- 2002-05-17 BR BR0209836-9A patent/BR0209836A/pt not_active IP Right Cessation
- 2002-05-17 EP EP02744162A patent/EP1395285A4/en not_active Withdrawn
- 2002-05-17 IL IL15875002A patent/IL158750A0/xx unknown
-
2008
- 2008-11-27 JP JP2008302849A patent/JP2009142274A/ja active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107760686A (zh) * | 2016-08-23 | 2018-03-06 | 上海伯豪医学检验所有限公司 | Dkk‑1蛋白的核酸适配体及其应用 |
| CN107760686B (zh) * | 2016-08-23 | 2021-04-16 | 上海伯豪医学检验所有限公司 | Dkk-1蛋白的核酸适配体及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009142274A (ja) | 2009-07-02 |
| IL158750A0 (en) | 2004-05-12 |
| JP2005512508A (ja) | 2005-05-12 |
| EP1395285A2 (en) | 2004-03-10 |
| WO2002092015A3 (en) | 2003-10-23 |
| EP1395285A4 (en) | 2005-06-01 |
| BR0209836A (pt) | 2004-12-07 |
| AU2002342734B2 (en) | 2007-07-26 |
| WO2002092015A2 (en) | 2002-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7700101B2 (en) | Reagents and method for modulating Dkk-mediated interactions | |
| AU2002342734B2 (en) | Reagents and methods for modulating Dkk-mediated interactions | |
| AU2002342734A1 (en) | Reagents and methods for modulating Dkk-mediated interactions | |
| Nakashiba et al. | Netrin-G1: a novel glycosyl phosphatidylinositol-linked mammalian netrin that is functionally divergent from classical netrins | |
| US7416849B2 (en) | HBM variants that modulate bone mass and lipid levels | |
| KR100603683B1 (ko) | 활막세포 단백질 | |
| WO2002006483A1 (fr) | Nouveau peptide actif sur le plan physiologique et utilisation associee | |
| KR20070084498A (ko) | Ｔｏｒｃ 폴리뉴클레오티드 및 폴리펩티드, 및 사용 방법 | |
| US20120039912A1 (en) | Rspondin-3 inhibition in bone disorders | |
| US8444975B2 (en) | Method for inhibiting bone resorption | |
| US20090226463A1 (en) | Novel method of modulating bone-related activity | |
| Bennett et al. | Odor-evoked gene regulation and visualization in olfactory receptor neurons | |
| EP2091556B1 (en) | Non-human animal comprising a mutation in the sreb2/gpr85 gene as animal model of metabolic disease | |
| US20070275872A1 (en) | Peptides with Anti-Obesity Activity and Other Related Uses | |
| JP2018528213A (ja) | 新規なｉｇｆｒ様レセプター及びその使用 | |
| JP2002345468A (ja) | 新規インスリン／ｉｇｆ／リラキシンファミリーポリペプチドおよびそのｄｎａ | |
| US7414109B2 (en) | FIAT nucleic acids and proteins and uses thereof | |
| JP2003526369A (ja) | 新規ポリヌクレオチドおよび同一物をコードする核酸 | |
| US20070092527A1 (en) | Proton-sensing g-protein coupled receptors and dna sequences thereof | |
| Bassi | A multidisciplinary approach to characterize the role of prokineticin receptor 2 (PROKR2) in Congenital Hypogonadotropic Hypogonadism (CHH) | |
| US20050283842A1 (en) | Mipp1 homologous nucleic acids and proteins involved in the regulation of energy homeostatis | |
| JP2003116582A (ja) | 新規生理活性ペプチドおよびその用途 | |
| Panda | Role of tuberoinfundibular peptide 39 (TIP 39)/parathyroid hormone 2 receptor (PTH2R) signalling in the control of endochondral bone formation | |
| Guo | Developmental regulation of lipid-droplet transport in Drosophila |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |